$ANAB posted great clinical results for a drug study....but the n-value (number in study) is insignificant. The company is years away from a product. A buyout is ~0% likely. ANAB will likely sell stock or debt to raise money. $ANAB, AnaptysBio, Inc. / H1 Avoid AnaptysBio. Comment below.Related: MannKind $MNKD is a stock to avoid, too. The warrant sale sets a ceiling of $2 on the stock. $MNKD, MannKind Corporation / H1 $MNK is another disaster. Avoid. $MNK, Mallinckrodt plc / H1 Bottom line: Avoid $ANAB.Agree or disagree?Login now to vote. Join the group of Value Stocks. With Over 800 members.